



This is a repository copy of *Exploring the antimicrobial properties of vaginal Lactobacillus crispatus against preterm birth-associated bacteria.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/190914/>

Version: Published Version

---

**Article:**

Amabebe, E. [orcid.org/0000-0002-3924-5270](https://orcid.org/0000-0002-3924-5270), Bhatnagar, N., Kamble, N. et al. (2 more authors) (2022) Exploring the antimicrobial properties of vaginal *Lactobacillus crispatus* against preterm birth-associated bacteria. *Reproduction and Fertility*, 3 (3). L6-L8. ISSN 2633-8386

<https://doi.org/10.1530/raf-22-0026>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## RESEARCH LETTER

# Exploring the antimicrobial properties of vaginal *Lactobacillus crispatus* against preterm birth-associated bacteria

Emmanuel Amabebe<sup>1</sup>, Noopur Bhatnagar<sup>1</sup>, Nitin Kamble<sup>2</sup>, Steven Reynolds<sup>3</sup> and Dilly O Anumba<sup>1</sup>

<sup>1</sup>Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK

<sup>2</sup>School of Dentistry, University of Sheffield, Sheffield, UK

<sup>3</sup>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

Correspondence should be addressed to D O Anumba: [d.o.c.anumba@sheffield.ac.uk](mailto:d.o.c.anumba@sheffield.ac.uk)

## Lay summary

The need to develop new treatments to prevent unprompted premature delivery before 37 weeks of pregnancy remains pressing and unmet. Bacteria (*Lactobacillus* species) that promote vaginal health produce biochemical compounds that prevent the growth of microbes such as *Gardnerella vaginalis*. Overgrowth of *G. vaginalis* can cause vaginal infection with smelly discharge and increase a woman's risk of sexually transmitted infections and premature delivery. In this study, we examined how normal health-promoting (*L. crispatus*) and potentially harmful (*G. vaginalis*) vaginal bacteria interact in a laboratory setting. This was in order to observe natural and effective agent(s) from *L. crispatus* that can hinder the growth of *G. vaginalis* and accompanying immune response. We observed that *L. crispatus* clears *G. vaginalis* by itself and with several biochemical compounds that it produces. Such biochemical compounds can be developed into treatment for vaginal infections and premature delivery due to infection and inappropriate immune response.

*Reproduction and Fertility* (2022) 3 L6–L8

The need to develop novel therapies to prevent spontaneous preterm birth (sPTB <37 weeks) remains pressing and unmet. PTB affects about 15 million births annually. It is the largest direct cause of death in children <5 years, with associated debilitating morbidity in surviving infants (Suff *et al.* 2019). Majority (70%) of PTBs occur spontaneously with significant contribution from ascending genital tract infections and inflammation (Romero *et al.* 2014). A dysbiotic vaginal microbiota can lead to an infectious inflammation with the release of proinflammatory cytokines such as IL-1, IL-6, RANTES that may initiate the pathway to delivery prematurely (Amabebe & Anumba 2018, Amabebe *et al.* 2018, 2019). *Lactobacillus* species (e.g. *Lactobacillus crispatus*) that promote vaginal health produce molecules that prevent the growth of microbes such as *Gardnerella vaginalis* that are associated with

common genital tract infections such as bacterial vaginosis (BV) and sPTB (Amabebe & Anumba 2018, 2022).

In order to explore the antimicrobial properties of vaginal *L. crispatus* against BV and sPTB-associated bacteria, we examined the interaction of *L. crispatus* and *G. vaginalis* *in vitro* to explore for natural and effective agent(s) from *L. crispatus* that inhibit the growth of *G. vaginalis* and probable associated inflammatory response.


Both *L. crispatus* (ATCC 33820, De Man, Rogosa and Sharpe) and *G. vaginalis* (ATCC 14019, brain heart infusion) were grown on their respective media and then co-incubated (1:5) on Columbia agar (CA, enriched with 5% horse blood or serum) under anaerobic condition: 80% N<sub>2</sub>, 10% CO<sub>2</sub>, and 10% H<sub>2</sub> at 37°C for 48 h. Three different preparations of *L. crispatus*: bacterial suspension (ULc), centrifuged not filtered (supernatant with fewer cells, UCLc), and filtered

supernatant from UCLc (cell-free supernatant, FLC) were co-incubated with *G. vaginalis* separately on CA. *L. crispatus* alone cultured on CA was used as control. After incubating for 48 h, bacterial growth was confirmed by Gram staining (Fig. 1A). Samples were extracted from the agar plates using a wet sterile Dacron swab and suspended in 600 µL phosphate buffered saline before analysis. Bacterial protein and metabolite expression were determined by liquid chromatography-mass spectrometry and proton NMR spectroscopy (<sup>1</sup>H-NMR).

*L. crispatus* produced a zone of inhibition (ZoI) on the media containing *G. vaginalis* that was more profound with ULc compared to UCLc and FLC samples (Fig. 1A). Proteins involved in carbohydrate fermentation – lactate dehydrogenase, α-glucosidase, pyruvate kinase, enolase, fructose-bisphosphate aldolase, and phosphoglycerate mutase (Fig. 1B); as well as antimicrobial, defence and survival/tolerance activities – bacteriocin helveticin J, S-layer protein, pyruvate oxidase, universal stress protein, and conserved protein with bacterial Ig like domain were observed in the ZoI but not in the *Gardnerella* region. These

proteins were of *L. crispatus* origin and only observed in ULc. Furthermore, metabolites with antimicrobial, anti-inflammatory, and antioxidant activities, that is, allicin were observed in the ZoI only (ULc and UCLc), while lactate and N-acetylneuraminic acid were higher in ZoI (ULc and FLC) compared to the corresponding *Gardnerella* regions.

*L. crispatus* inhibits the growth of *G. vaginalis* *in vitro* induced by antimicrobial and anti-inflammatory agents. Although the cell-free supernatant of *L. crispatus* also inhibited the growth of *G. vaginalis*, both *L. crispatus* and its by-products are required for more potent inhibition of *G. vaginalis*. That is, *L. crispatus* showed potential to inhibit a dysbiotic vaginal microbiota and infectious inflammation that may initiate the pathway to sPTB. Lactic acid, bacteriocin, S-layer protein, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) produced by metabolism of pyruvate to acetyl phosphate by pyruvate oxidase (Fig. 1B), and other antimicrobial proteins and metabolites are involved. The eubiotic, antimicrobial, prebiotic, and anti-inflammatory actions of some of these compounds especially lactic acid, H<sub>2</sub>O<sub>2</sub> (Fig. 1B), and bacteriocins have been reported.



**Figure 1** *Lactobacillus crispatus* inhibits growth of *Gardnerella vaginalis*. (A) Gram staining showing zone of inhibition (ZoI, Gram-positive rods – *L. crispatus* morphotypes, and its by-products) and peripheral zone (small Gram-negative cocci – *G. vaginalis* morphotypes). (B) Production of lactate and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), the two most widely studied antimicrobial metabolites of lactobacilli. Three different preparations of *L. crispatus*: bacterial suspension in De Man, Rogosa and Sharpe media, centrifuged not filtered (supernatant with fewer cells), and filtered supernatant from centrifuged sample (cell-free supernatant) were co-incubated with *G. vaginalis* separately on Columbia agar (CA, enriched with 5% horse blood or serum). *L. crispatus* was cultured alone on CA as control. After incubation for 48 h, bacterial growth was confirmed by Gram staining. ACK, acetate kinase; LDH, lactate dehydrogenase; LOX, lactate oxidase; PDH, pyruvate dehydrogenase; PFL, pyruvate formate lyase; PTA, phosphotransacetylase; POX, pyruvate oxidase.

The growth profile of *G. vaginalis* in the ZOI may have been affected by the presence of lactic acid that contribute to a reduction in pH and enhances the antimicrobial activities of H<sub>2</sub>O<sub>2</sub> that induces oxidative stress, and bacteriocins that are bactericidal (Kalyoussef *et al.* 2012, Amabebe & Anumba 2018, Happel *et al.* 2020, Klotz *et al.* 2020). The pH of the bacterial growth media (pH ~7.3) is different from that of the normal vaginal milieu (pH 3.5–4.5) (Amabebe & Anumba 2018), and this may have impacted the findings and implications of this study. Therefore, subsequent experiments should involve the co-incubation of the species in a single medium such as an artificial vaginal fluid (pH 4.1 adjusted) that simulates the normal vaginal microenvironment. Further investigation of the antimicrobial proteins and metabolites can contribute to the formulation of effective preventive and/or therapeutic interventions against infection-inflammation-associated sPTB. Their antimicrobial or anti-inflammatory properties can be tested singly and in combination. Lastly, the antimicrobial properties of other *Lactobacillus* spp. against common vaginal pathogens co-incubated with vaginal epithelial cells can also be explored.

#### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this letter.

#### Funding

This study was funded by University of Sheffield, UK, as part of Noopur's MSc in Reproductive and Developmental Medicine research project 2019.

#### Author contribution statement

E A, N K, and D A designed the study. N B, E A, N K, and S R performed the experiments. N B and E A analysed the mass spectrometry data. S R and E A processed and analysed the <sup>1</sup>H-NMR data. All authors contributed to writing the manuscript led by E A. All authors read and approved the final manuscript for submission.

#### Acknowledgements

The authors would like to thank Dr Adelina E Acosta Martin and Dr Heather Walker of the biOMICS Facility, Faculty of Science Mass Spectrometry

Centre, University of Sheffield, UK, for assisting with the mass spectrometry experiments and analyses; and Mr Jason Heath, School of Dentistry, University of Sheffield, UK, for the bacterial culture technical support. Part of this work was presented in the Preterm Birth Dialogues Conference 2021 organised by NIHR Global Health Research Group on Preterm birth prevention and management (PRIME, <https://www.primeglobalhealth.co.uk/>), and was awarded the second prize for oral presentation. The abstract was also published in Frontiers Event Abstracts 2021. 27–28. DOI: 10.3389/978-2-88966-550-1.

## References

- Amabebe E & Anumba DOC** 2018 The vaginal microenvironment: the physiologic role of lactobacilli. *Frontiers in Medicine* **5** 181. (<https://doi.org/10.3389/fmed.2018.00181>)
- Amabebe E & Anumba DOC** 2022 Mechanistic insights into immune suppression and evasion in bacterial vaginosis. *Current Microbiology* **79** 84. (<https://doi.org/10.1007/s00284-022-02771-2>)
- Amabebe E, Chapman DR, Stern VL, Stafford G & Anumba DOC** 2018 Mid-gestational changes in cervicovaginal fluid cytokine levels in asymptomatic pregnant women are predictive markers of inflammation-associated spontaneous preterm birth. *Journal of Reproductive Immunology* **126** 1–10. (<https://doi.org/10.1016/j.jri.2018.01.001>)
- Amabebe E, Reynolds S, He X, Wood R, Stern V & Anumba DOC** 2019 Infection/inflammation-associated preterm delivery within 14 days of presentation with symptoms of preterm labour: a multivariate predictive model. *PLoS ONE* **14** e0222455. (<https://doi.org/10.1371/journal.pone.0222455>)
- Happel AU, Kullin B, Gamielidien H, Wentzel N, Zauchenberger CZ, Jaspan HB, Dabee S, Barnabas SL, Jaumdally SZ, Dietrich J, et al.** 2020 Exploring potential of vaginal *Lactobacillus* isolates from South African women for enhancing treatment for bacterial vaginosis. *PLoS Pathogens* **16** e1008559. (<https://doi.org/10.1371/journal.ppat.1008559>)
- Kalyoussef S, Nieves E, Dinerman E, Carpenter C, Shankar V, Oh J, Burd B, Angeletti RH, Buckheit KW, Fredricks DN, et al.** 2012 *Lactobacillus* proteins are associated with the bactericidal activity against *E. coli* of female genital tract secretions. *PLoS ONE* **7** e49506. (<https://doi.org/10.1371/journal.pone.0049506>)
- Klotz C, Goh YJ, O'Flaherty S, Johnson B & Barrangou R** 2020 Deletion of S-layer associated Ig-like domain protein disrupts the *Lactobacillus acidophilus* cell surface. *Frontiers in Microbiology* **11** 345. (<https://doi.org/10.3389/fmicb.2020.00345>)
- Romero R, Dey SK & Fisher SJ** 2014 Preterm labor: one syndrome, many causes. *Science* **345** 760–765. (<https://doi.org/10.1126/science.1251816>)
- Suff N, Story L & Shennan A** 2019 The prediction of preterm delivery: what is new? *Seminars in Fetal and Neonatal Medicine* **24** 27–32. (<https://doi.org/10.1016/j.siny.2018.09.006>)

Received in final form 16 May 2022

Accepted 18 July 2022

Accepted Manuscript published online 18 July 2022